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Background: The prognostic role of serum estrogen level in breast cancer patients is unclear. We investigated the
prognostic importance of preoperative serum estradiol (E2) level in postmenopausal women according to their
estrogen receptor (ER) status.
Methods: The medical records of 313 postmenopausal breast cancer patients who underwent surgery between
2006 and 2008 at a single institution were retrospectively evaluated. Patients who received neoadjuvant
chemotherapy, synchronous bilateral breast cancer, or those with metastasis at diagnosis were excluded. Serum E2
and follicular stimulating hormone (FSH) levels were measured by radioimmunoassay and immunoradiometric
assay, respectively, within 3 months prior to surgery. After a median follow-up of 52.0 months (11–77 months), 21
women were found to have metastatic disease.
Results: The overall, median E2 level was 13.0 pg/ml, and was slightly higher in ER-positive than ER-negative
(p=0.69). The mean serum E2 level was significantly higher in patients with metastasis (17.41±8.34 pg/ml) than in
those without metastasis (13.54±7.58 pg/ml) (p=0.02). Kaplan-Meier analysis using a cut-off of 13 pg/ml showed
that, ER negative (p=0.02) but not ER positive (p>0.05) patients with higher E2 level showed significantly poorer
metastasis-free survival. Multivariate analysis showed that, the high E2 level of ER negative tumors was an
independent negative prognostic factor for metastasis- free survival (HR, 3.32; 95% CI, 1.05 to 10.51; p=0.04).
Conclusions: Higher preoperative serum E2 level had a negative prognostic effect in postmenopausal women with
breast cancer, especially in the ER-negative subgroup.
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Many epidemiologic and experimental studies support
an association between higher serum levels of sex steroid
hormones and an increased risk of postmenopausal
breast cancer, especially for estrogen receptor (ER)-posi-
tive breast cancers [1-6]. However, the prognostic role of
the serum level of these hormones in newly diagnosed
breast cancer patients is still unclear. Although several
studies have reported that higher serum testosterone
levels at diagnosis were associated with poor prognosis
in postmenopausal women with breast cancer, other
studies demonstrated no such association [7-9]. The role* Correspondence: hanw@snu.ac.kr
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reproduction in any medium, provided the orof testosterone in breast cancer has been attributed to
its conversion to estrogen by aromatase.
Estrogen has been found to contribute significantly to
breast tumor formation and growth [10-13]. High serum
estradiol levels were reported to be associated with spe-
cific gene expression patterns in breast cancer tissue.
[14]. In estrogen-dependent tumors, estrogen promotes
cell proliferation and, suppresses apoptosis, by directly
modulating gene transcription, making estrogen an im-
portant target in treatment [15].
ER status is important in breast cancer carcinogen-
esis and progression. Circulating estrogen binds to ER
in breast cancer cells and stimulates cell division and
growth. However, recent studies provided further mo-
lecular insights into the estradiol-dependent breast. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pendently of ER [16-18].
Serum estradiol level is significantly lower in post-
menopausal than in premenopausal women. And post-
menopausal women have been consistent in E2 levels
without variation according to menstrual cycle. Here,
we report the results of a single-institutional retrospective
analysis of the prognostic importance of preoperative
serum estradiol level in postmenopausal breast cancer pa-
tients. Our hypothesis is that serum estradiol level may be
significant prognostic factor in postmenopausal breast
cancer.
Methods
The Seoul national university hospital breast care center
database was reviewed for the medical records of post-
menopausal women who underwent curative surgery
between September 2006 and December 2008 for newly
diagnosed invasive breast cancer and for whom we had
the information on serum estradiol levels within 3 months
prior to surgery. Patients who received neoadjuvant
chemotherapy, synchronous bilateral breast cancer or
those with metastasis at diagnosis time were excluded
from the study. Women were defined as postmeno-
pausal if they had a bilateral oophorectomy, were aged
60 years or older, or were aged under 60 years with
amenorrhea for at least 12 months, and their serumFigure 1 Flow chart of patients’ selection.follicular stimulating hormone (FSH) levels satisfied the
diagnostic criteria for menopause (FSH>30 mIU/mL).
We identified 313 postmenopausal women eligible for
the study (Figure 1).
Serum levels of E2 were measured by radioimmuno-
assay (RIA) using commercial kits (Biosource, Nivelles,
Belgium), with intra- and inter-assay coefficients of
variation (CV) of 4.9% and 5.2%, respectively. FSH were
measured by immunoradiometric assay (IRMA) using
commercial kits (Biosource), with a detection limit of
0.1 mlU/mL, and intra- and inter assay CVs of 3.3% and
7.1%, respectively.
Pathology data, including tumor size, grade, lymph node
involvement, and immunohistochemistry results on hor-
mone receptors expression, were reviewed. A cut-off value
of 1% or more positively stained nuclei in the high-power
fields was used to define ER and PR positivity. Patients
were recommended to undergo adjuvant therapy and
surveillance according to the St Gallen and/or NCCN
guidelines.
Distant metastasis excluded local breast recurrence,
axillary lymph node recurrence and newly diagnosed
contralateral breast cancer. The time of metastasis was
defined as the date confirmed by biopsy or image find-
ing. Metastasis-free survival defined as the time period
from the date of breast surgery to that of first diagnosis
with distant metastasis by biopsy results or image or last
Table 1 The clinical and histopathological characteristics
of the included patients
Characteristics Number of patients (% of total)
Total ER positive ER negative P value
Enrolled patients 313 190 123
Tumor size (mean), cm 2.17 2.03 2.40
<2 170 121(63.7%) 49(39.8%) <0.001
2-5 138 65(34.2%) 73(59.3%)
≥5 5 4(2.1%) 1(0.8%)
Nodal status
0 206 130(68.4%) 76(61.8%) 0.310
1-3 81 44(23.2%) 37(30.1%)
4-9 14 7(3.7%) 7(5.7%)
≥10 12 9(4.7%) 3(2.4%)
Nuclear grade <0.001
Grade 1 or 2 127 109(57.4%) 18(14.6%)
Grade 3 175 76(40.0%) 99(80.5%)
Unknown 11 5(2.6%) 6(4.9%)
Histologic grade <0.001
Grade 1 or 2 131 113(59.5%) 18(14.6%)
Grade 3 153 59(31.0%) 94(76.4%)
Unknown 29 18(9.5%) 11(9.0%)
PR status <0.001
Positive 133 128(67.4%) 5(4.1%)
Negative 180 62(32.6%) 118(95.9%)
HER2/neu status <0.001
Positive 45 9(4.7%) 36(29.3%)
Negative 246 170(89.5%) 76(61.8%)
Unknown 22 11(5.8%) 11(8.9%)
Operation 0.014
Conservation 175 117(61.6%) 58(47.2%)
Mastectomy 138 73(38.4%) 65(52.8%)
Adjuvant chemotherapy <0.001
No 131 103(54.2%) 28(22.8%)
Yes 182 87(45.8%) 95(77.2%)
Adjuvant Radiotherapy 0.129
No 133 74(38.9%) 59(48.0%)






Distant metastasis 7(3.7%) 15(12.2%) 0.006
Abbreviations: ER estrogen receptor, PR Progesterone receptor, SERM selective
estrogen modulator, AI aromatase inhibitor.
Switch*: Tamoxifen for 2–3 year, and then aromatase inhibitor to complete
5 year.
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identify significant independent factors related to distant
metastasis.
Student’s t-tests were used to compare E2 levels in
two groups, and Pearson's correlation test was used to
test the relationships between E2 level and age and
body mass index (BMI). The Kaplan-Meier method
and log-rank test were used for survival analysis. The
Cox regression model was utilized to identify signifi-
cant independent factors related to distant metastasis.
The variables included in the final model were defined
by backward selection. We excluded the missing or un-
known data when we performed statistical analysis.
Significance was defined as p<0.05. All statistical ana-
lyses were performed using SPSS (version 19.0 SPSS
Inc., Chicago, IL, USA). Written informed consent was
taken prior to surgery in all patients and the study
protocol including the use of the database was approved
by the Institutional Review Board of Seoul National Uni-
versity Hospital and met the guidelines of the responsible
governmental agencies.
Results
The clinical and histopathological characteristics of the
studied patients are listed in Table 1. Patients ranged in
age from 45 to 83 years, with 3 patients having under-
gone bilateral oophorectomy before diagnosis of breast
cancer. Of the 195 patients with ER or PR positive tumors,
192 received adjuvant hormonal therapy.
The overall median level of estradiol was 13.0 pg/ml,
with mean estradiol levels higher in patients with ER
positive than ER negative tumors (14.36±7.85 pg/ml vs.
12.97 ± 7.37 pg/ml, p=0.69) (Table 2). Serum levels of
estradiol did not correlate with age (Pearson correlation
coefficient=0.033, p=0.56) or BMI (Pearson correlation
coefficient =0.106, p=0.06).
During a median follow-up time of 52.0 months after
diagnosis (range, 11 to 77 months), 3 patients had locor-
egioanl recurrence, 2 patients had contralateral breast
cancer, and 21 patients had distant metastasis as the first
event. And one patient with local recurrence eventually
had distant metastasis. As the results, 22 patients were
diagnosed with distant metastases, 7 in the ER positive
and 15 in the ER negative group. Mean serum estradiol
level was significantly higher in patients with than with-
out metastasis (17.41±8.34 pg/ml vs. 13.54±7.58 pg/ml,
p=0.02).
We performed Kaplan-Meier survival analysis to
evaluate the prognostic effect of estradiol according to
ER status. Using the cut-off values 13 pg/ml, which is
the median value in this study, we found that metastasis
free survival was lower in ER-positive patients with higher
than with lower estradiol level, although the difference
was not statistically significant (Figure 2a). In ER negative




Tumor size <2 cm 13.69±7.17 0.75
≥2 cm 13.97±8.28
Nodal status N0 13.93±7.99 0.71
N1-3 13.59±7.09
ER Negative 12.97±7.37 0.69
Positive 14.36±7.85
PR Negative 13.41±7.52 0.27
Positive 14.37±7.89
Her-2 Negative 14.09±7.80 0.81
Positive 14.40±7.33
Histologic grade Grade 1 or 2 13.91±8.05 0.80
Grade 3 13.68±7.25
Nuclear grade Grade 1 or 2 13.78±8.38 0.89
Grade 3 13.90±7.11
Abbreviations: SD Standard deviation, ER estrogen receptor, PR Progesterone
receptor.
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ciated with increased risk of metastasis (Log-rank=0.02)
(Figure 2b).
To confirm the prognostic effect of serum estradiol in
ER negative breast cancer patients, we performed a multi-
variate analysis using a Cox hazard model. The estradiol
level was found to be an independent negative prognostic
indicator of metastasis free survival (HR, 3.32; 95% CI,
1.05 to 10.51; p=0.04) (Table 3).
We also found that, ER negative patients with higher
estradiol levels were significantly associated with in-



























E2 ≤ 13 pg/ml
E2  >13 pg/ml
a)                ER positive group
Figure 2 Metastasis-free survivals according to ER status. a. Metastasis
lower estradiol level, although the difference was not statistically significan
were significantly associated with increased risk of metastasis (Log-rank=0.0locoregional recurrence and contralateral recurrence).
(Log rank=0.034) In multivariate analysis using a Cox
hazard model, high E2 (>13 pg/ml) of ER negative tu-
mors was negative prognostic factor for disease-free
survival (HR, 2.717), but the p value was 0.058.
Discussion
We have shown here that higher serum estrogen levels
contribute to the risk of distant metastasis in postmeno-
pausal breast cancer patients with ER negative tumors.
Rock et al. [7] have also shown the significant associ-
ation between serum estradiol level and patient’s survival
in a nested case–control cohort of a randomized trial of
diet intervention (Women’s Health Eating and Living
study), although that study did not include subgroup
analysis based on ER expression status.
Our observation, that serum estradiol level affects
prognosis only in patients with ER negative tumors, was
interesting since estradiol is thought to play a key role in
the carcinogenesis of ER positive tumors. Indeed, our
findings are supported by recent experimental studies
showing that estradiol regulates the progression of ER
negative breast cancer cell lines. For example, Gupta
et al. [16] reported that estrogen promotes the growth,
stromalization, and angiogenesis of an ER negative breast
cancer cell line by systemic induction of host angiogenesis
and bone marrow-derived stromal cell recruitment. Simi-
larly, Banka et al. [17] showed that estradiol treatment of
ovariectomized mice injected with an ER negative mouse
mammary carcinoma cell line markedly increased the inci-
dence of lung metastasis. These studies suggest that estra-
diol can act as a potent metastasis-promoter in ER
negative tumors by a novel mechanism involving the host



























b)                ER negative group
-free survival was lower in ER-positive patients with higher than with
t (Log-rank=0.25). b. In ER negative patients, higher estradiol levels
2).
Table 3 Univariate and multivariate analyses of prognostic factors including serum E2 level for metastasis-free survival
according to ER status
ER positive group ER negative group
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value
Age 1.06 0.97-1.16 0.24 1.02 0.95-1.09 0.63
BMI, ≥23 kg/m2 1.22 0.52-2.86 0.64 1.02 0.37-2.82 0.97
HER2/neu positive 0.99 0.98-1.01 0.69 0.97 0.33-2.84 0.96
Tumor size, >2 cm 10.65 1.28-88.48 0.03 3.75 0.41-33.98 0.24 4.75 1.07-21.06 0.04 1.85 0.37-9.27 0.45
Node metastasis
0 Ref. Ref. Ref.
1-3 1.47 0.13-16.25 0.75 1.12 0.10-12.66 0.93 4.00 1.17-13.70 0.03 2.45 0.65-9.31 0.19
>3 18.96 3.47-103.63 0.001 9.05 1.50-54.45 0.02 10.70 2.67-42.90 0.001 2.99 0.62-14.36 0.17
Nuclear grade 3 3.06 1.06-8.83 0.04 1.21 0.08-19.62 0.87 1.11 0.53-2.34 0.78
Histologic grade 3 3.59 1.24-10.38 0.02 8.04 0.54-120.81 0.13 1.16 0.55-2.45 0.69
ELTE 2.91 0.65-13.00 0.16 8.28 2.63-26.06 <0.001 4.24 1.18-15.18 0.03
E2 level, >13 pg/ml 2.54 0.49-13.13 0.27 3.373 1.07-10.61 0.04 3.32 1.05-10.51 0.04
Chemotherapy 2.49 0.92-6.75 0.07
A multivariate analysis was set by using all of the predictors with p values under 0.05 in univariate analysis.
Abbreviations: ER estrogen receptor, BMI Body mass index, ELTE endolymphatic tumor emboli, E2 Estradiol.
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breast tumors are associated with higher estrogen levels
because they share a common cause, for example, such tu-
mors could elicit a strong inflammatory response which
both enables metastasis and also upregulates aromatase
activity in surrounding tissues.
Indirect evidence supporting the role of estradiol in
ER negative tumor development can also be found in
human clinical studies. Ovariectomy was shown to signi-
cantly reduce the incidence of both ER negative and ER
positive tumors [19,20]. Prophylactic oophorectomy can
prevent the development of breast cancers in BRCA1
mutation carriers in whom the main types of breast can-
cer are ER negative [21-23]. However, it is unclear
whether it may be the consequence of inhibition of the
transition of luminal of ER positive cells to negative or
inhibition of tumorigenesis itself. And among BRCA1
mutation carriers older than age 50, no risk reduction
was evident with prophylactic oophorectomy [23]. It is
also unclear whether the estrogen lowering treatments
like aromatase inhibitors were effective in ER negative
tumors. According to the study of Jones et al. [24] which
was central review of pathological specimens from pa-
tients entered in BIG 1–98 trials, aromatase inhibitors
might have advantage in only patients whose tumor ex-
press ER. However, they didn’t measure the preoperative
estradiol level, so it was impossible to compare the dif-
ference of effect according to estradiol level in patients
with ER negative or positive tumors.
It is unclear why serum estradiol level was not signifi-
cantly associated with the development of metastasis inER positive breast cancer patients. One possible explan-
ation is that almost all patients with ER positive tumors
in our study cohort (98.4%) received anti-estrogen treat-
ment with either tamoxifen or aromatase inhibitors. In
addition, there were fewer events in ER positive tumors,
so it might act as cause of limited power.
Premenopausal women experience changes in their
serum estrogen levels throughout their menstrual cycles.
In contrast, postmenopausal women have been more con-
sistent in E2 levels, because of the absence of the variabil-
ity of hormone levels with the menstrual cycle. Therefore,
to analysis the difference of prognosis according to serum
E2 level in premenopausal women, constant measure of
E2 in time is important.
This study has several limitations. Due to its retrospect-
ive nature, there may have been a selection bias. Specially,
the measurement of estradiol levels was not performed as
a part of the prospective design. Some were measured for
other studies, and others measured for standard element
of the work-up for breast cancer by special physicians dur-
ing different periods. Also, the median follow-up period of
52 months was not sufficient to assess the prognostic ef-
fect in breast cancer patients, especially in patients with
ER positive tumors. And our findings are based on a quite
small number of cases. Further confirmatory studies are
needed.
Conclusions
We found that a higher level of serum estradiol had a
negative prognostic effect in postmenopausal women with
ER negative breast cancer. These findings are hypothesis
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ment can facilitate the progression of ER negative tumors.
Additional in vivo and prospective cohort studies are
needed to address this hypothesis.
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